

**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 10:50AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### CLINICAL CHEMISTRY/BIOCHEMISTRY LIVER FUNCTION TEST (COMPLETE)

BILIRUBIN TOTAL: SERUM <i>by DIAZOTIZATION, SPECTROPHOTOMETRY</i>	0.52	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
BILIRUBIN DIRECT (CONJUGATED): SERUM <i>by DIAZO MODIFIED, SPECTROPHOTOMETRY</i>	0.17	mg/dL	0.00 - 0.40
BILIRUBIN INDIRECT (UNCONJUGATED): SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	0.35	mg/dL	0.10 - 1.00
SGOT/AST: SERUM <i>by IFCC, WITHOUT PYRIDOXAL PHOSPHATE</i>	16.3	U/L	7.00 - 45.00
SGPT/ALT: SERUM <i>by IFCC, WITHOUT PYRIDOXAL PHOSPHATE</i>	13.8	U/L	0.00 - 49.00
AST/ALT RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	1.18	RATIO	0.00 - 46.00
ALKALINE PHOSPHATASE: SERUM <i>by PARA NITROPHENYL PHOSPHATASE BY AMINO METHYL PROPANOL</i>	213.52	U/L	50.00 - 370.00
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM <i>by SZASZ, SPECTROPHOTOMETRY</i>	12.01	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM <i>by BIURET, SPECTROPHOTOMETRY</i>	7.07	gm/dL	6.20 - 8.00
ALBUMIN: SERUM <i>by BROMOCRESOL GREEN</i>	4.22	gm/dL	3.50 - 5.50
GLOBULIN: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	2.85	gm/dL	2.30 - 3.50
A : G RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	1.48	RATIO	1.00 - 2.00

#### INTERPRETATION

**NOTE:-** To be correlated in individuals having SGOT and SGPT values higher than Normal Reference Range.

**USE:-** Differential diagnosis of diseases of hepatobiliary system and pancreas.

#### INCREASED:

DRUG HEPATOTOXICITY	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5



  
 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 10:50AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS	> 1.3 (Slightly Increased)		


**DECREASED:**


1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)
2. Extra Hepatic cholestasis: 0.8 (normal or slightly decreased).

**PROGNOSTIC SIGNIFICANCE:**

NORMAL	< 0.65
GOOD PROGNOSTIC SIGN	0.3 - 0.6
POOR PROGNOSTIC SIGN	1.2 - 1.6



  
**DR.VINAY CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
**DR.YUGAM CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 11:04AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### ENDOCRINOLOGY

#### LUTEINISING HORMONE (LH)

LUTEINISING HORMONE (LH): SERUM	15.81	mIU/mL	MALES: 0.57 - 12.07 FOLLICULAR PHASE: 1.80 - 11.78 MID-CYCLE PEAK: 7.59 - 89.08 LUTEAL PHASE: 0.56 - 14.0 POST MENOPAUSAL WITHOUT HRT: 5.16 - 61.99
<i>by CMIA (CHEMILUMINESCENT PARTICLE IMMUNOASSAY)</i>			

#### INTERPRETATION:

- Luteinizing hormone (LH) is a glycoprotein hormone consisting of 2 non covalently bound subunits (alpha and beta). Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, FSH and LH, from the anterior pituitary.
- In both males and females, LH is essential for reproduction. In females, the menstrual cycle is divided by a mid cycle surge of both LH and FSH into a follicular phase and a luteal phase.
- This "LH surge" triggers ovulation thereby not only releasing the egg, but also initiating the conversion of the residual follicle into a corpus luteum that, in turn, produces progesterone to prepare the endometrium for a possible implantation.
- LH supports thecal cells in the ovary that provide androgens and hormonal precursors for estradiol production. LH in males acts on testicular interstitial cells of Leydig to cause increased synthesis of testosterone.

#### The test is useful in the following situations:

- An adjunct in the evaluation of menstrual irregularities.
- Evaluating patients with suspected hypogonadism
- Predicting ovulation & Evaluating infertility
- Diagnosing pituitary disorders
- In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone and luteinizing hormone levels.

#### FSH AND LH ELEVATED IN:

- Primary gonadal failure
- Complete testicular feminization syndrome
- Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
- Menopause
- Primary ovarian hypo dysfunction in females
- Polycystic ovary disease in females
- Primary hypogonadism in males

#### LH IS DECREASED IN:

- Primary ovarian hyper function in females
- Primary hypergonadism in males

#### NOTE

- FSH and LH are both decreased in failure of the pituitary or hypothalamus.



  
 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

Dr. Yugam Chopra  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 11:04AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### FOLLICLE STIMULATING HORMONE (FSH)

FOLLICLE STIMULATING HORMONE (FSH): SERUM	5.26	mIU/mL	FEMALE FOLLICULAR PHASE: 3.03 - 8.08
by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)			FEMALE MID-CYCLE PEAK: 2.55 - 16.69
			FEMALE LUTEAL PHASE: 1.38 - 5.47
			FEMALE POST-MENOPAUSAL: 26.72 - 133.41
			MALE: 0.95 - 11.95

#### INTERPRETATION:

1. Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary.
2. The menstrual cycle is divided by a midcycle surge of both FSH and LH into a follicular phase and a luteal phase.
3. FSH appears to control gametogenesis in both males and females.

#### The test is useful in the following settings:

1. An adjunct in the evaluation of menstrual irregularities.
2. Evaluating patients with suspected hypogonadism.
3. Predicting ovulation
4. Evaluating infertility
5. Diagnosing pituitary disorders
6. In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels.

#### FSH and LH LEVELS ELEVATED IN:

1. Primary gonadal failure
2. Complete testicular feminization syndrome.
3. Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
4. Menopause (postmenopausal FSH levels are generally >40 IU/L)
5. Primary ovarian hypofunction in females
6. Primary hypogonadism in males

#### NOTE:

1. Normal or decreased FSH is seen in polycystic ovarian disease in females
2. FSH and LH are both decreased in failure of the pituitary or hypothalamus.





DR. VINAY CHOPRA  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)



DR. YUGAM CHOPRA  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 11:04AM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### PROLACTIN

PROLACTIN: SERUM	16.43	ng/mL	3 - 25
------------------	-------	-------	--------

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

#### INTERPRETATION:

1. Prolactin is secreted by the anterior pituitary gland and controlled by the hypothalamus.  
 2. The major chemical controlling prolactin secretion is dopamine, which inhibits prolactin secretion from the pituitary.  
 3. Physiological function of prolactin is the stimulation of milk production. In normal individuals, the prolactin level rises in response to physiologic stimuli such as sleep, exercise, nipple stimulation, sexual intercourse, hypoglycemia, postpartum period, and also is elevated in the newborn infant.

#### INCREASED (HYPERPROLACTEMIA):

1. Prolactin-secreting pituitary adenoma (prolactinoma, which is 5 times more frequent in females than males).  
 2. Functional and organic disease of the hypothalamus.  
 3. Primary hypothyroidism.  
 4. Section compression of the pituitary stalk.  
 5. Chest wall lesions and renal failure.  
 6. Ectopic tumors.  
 7. DRUGS:- Anti-Dopaminergic drugs like antipsychotic drugs, anti-nausea/antiemetic drugs, Drugs that affect CNS serotonin metabolism, serotonin receptors, or serotonin reuptake (anti-depressants of all classes, ergot derivatives, some illegal drugs such as cannabis), Antihypertensive drugs, Opiates, High doses of estrogen or progesterone, anticonvulsants (valproic acid), anti-tuberculous medications (Isoniazid).

#### SIGNIFICANCE:

1. In loss of libido, galactorrhea, oligomenorrhea or amenorrhea, and infertility in premenopausal females.  
 2. Loss of libido, impotence, infertility, and hypogonadism in males. Postmenopausal and premenopausal women, as well as men, can also suffer from decreased muscle mass and osteoporosis.  
 3. In males, prolactin levels >13 ng/mL are indicative of hyperprolactinemia.  
 4. In women, prolactin levels >27 ng/mL in the absence of pregnancy and postpartum lactation are indicative of hyperprolactinemia.  
 5. Clear symptoms and signs of hyperprolactinemia are often absent in patients with serum prolactin levels <100 ng/mL.  
 4. Mild to moderately increased levels of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary adenoma is present, 5. Whereas levels >250 ng/mL are usually associated with a prolactin-secreting tumor.

#### CAUTION:

Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin). Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent, or pituitary imaging studies are not informative.



  
 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 12:05PM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

### ANTI MULLERIAN HORMONE (AMH) GEN II

ANTI MULLERIAN HORMONE (AMH) GEN II: SERUM 3.336 ng/mL 0.05 - 11.00  
 by ECLIA (ELECTROCHEMILUMINESCENCE IMMUNOASSAY)

#### INTERPRETATION:-

A Correlation of FERTILITY POTENTIAL and AMH levels are :

OVARIAN FERTILITY POTENTIAL	AMH VALUES IN (ng/mL)
OPTIMAL FERTILITY:	4.00 – 6.80 ng/mL
SATISFACTORY FERTILITY:	2.20 – 4.00 ng/mL
LOW FERTILITY:	0.30 – 2.20 ng/mL
VERY LOW/UNDETECTABLE:	0.00 – 0.30 ng/mL
HIGH LEVEL:	>6.8 ng/mL (PCOD/GRANULOSA CELL TUMOUR)

Anti Mullerian Hormone (AMH) is also known as Mullerian Inhibiting Substance provided by sertoli cells of the testis in males and by ovarian granulosa cells in females upto antral stage in females.

#### IN MALES:

1.It is used to evaluate testicular presence and function in infants with intersex conditions or ambiguous genitalia, and to distinguish between cryptorchidism and anorchia in males


#### IN FEMALES:


- 1.During reproductive age, follicular AMH production begins during the primary stage, peaks in preantral stage & has influence on follicular sensitivity to FSH which is important in selection for follicular dominance. AMH levels thus represents the pool or number of primordial follicles but not the quality of oocytes. AMH does not vary significantly during menstrual cycle & hence can be measured independently of day of cycle.
- 2.Polycystic ovarian syndrome can elevate AMH 2 to 5 fold higher than age specific reference range & predict anovulatory, irregular cycles, ovarian tumours like Granulosa cell tumour are often associated with higher AMH levels.
- 3.Obese women are often associated with diminished ovarian reserve and can have 65% lower mean AMH levels than non-obese women.
- 4.In females , AMH levels do not change significantly throughout the menstrual cycle and decrease with age.
- 5.Assess Ovarian Reserve - correlates with the number of antral follicles in the ovaries.
- 6.Evaluate fertility potential and ovarian response in IVF- Women with low AMG levels are more likely to the poor ovarian responders.
- 7.Assess the condition of Polycystic Ovary and premature ovarian failure.

A combination of Age, Ultrasound markers-Ovarian Volume and Antral Follicle Count, AMH and FSH levels are useful for optimal assessment of ovarian reserve. Studies in various fertility clinics are ongoing to establish optimal AMH concentration for predicting response to invitro fertilization, however, given below is suggested interpretative reference.

AMH levels (ng/mL)	Suggested patient	Anticipated Antral	Anticipated FSH levels	Anticipated Response
--------------------	-------------------	--------------------	------------------------	----------------------



  
**DR.VINAY CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
**DR.YUGAM CHOPRA**  
 CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)



**Dr. Vinay Chopra**  
 MD (Pathology & Microbiology)  
 Chairman & Consultant Pathologist

**Dr. Yugam Chopra**  
 MD (Pathology)  
 CEO & Consultant Pathologist

<b>NAME</b>	: Miss. HARLEEN KAUR	<b>PATIENT ID</b>	: 1713921
<b>AGE/ GENDER</b>	: 13 YRS/FEMALE	<b>REG. NO./LAB NO.</b>	: 012501020014
<b>COLLECTED BY</b>	:	<b>REGISTRATION DATE</b>	: 02/Jan/2025 09:43 AM
<b>REFERRED BY</b>	: DR. AMITA SINGHANIA	<b>COLLECTION DATE</b>	: 02/Jan/2025 09:45AM
<b>BARCODE NO.</b>	: 01523320	<b>REPORTING DATE</b>	: 02/Jan/2025 12:05PM
<b>CLIENT CODE.</b>	: KOS DIAGNOSTIC LAB		
<b>CLIENT ADDRESS</b>	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval	
	Categorization for fertility based on AMH for age group (20 to 45 yrs)	Follicle counts	(day 3)	to IVF/COH cycle
Below 0.3	Very low	Below 4	Above 20	Negligible/Poor
0.3 to 2.19	Low	4 - 10	Usually 16 - 20	Reduced
2.19 to 4.00	Satisfactory	11 - 25	Within reference range or between 11 - 15	Safe/Normal
Above 4.00	Optimal	Upto 30 and Above	Within reference range or between 11 – 15 or Above 15	Possibly Excessive

#### INCREASED:

1. Polycystic ovarian syndrome (most common)
2. Ovarian Tumour: Granulosa cell tumour

#### DECREASED:

1. Anorchia , Abnormal or absence of testis in males
2. Pseudohermaphroditism
3. Post Menopause

#### NOTE:

1. AMH measurement alone is seldom sufficient for diagnosis and results should be interpreted in the light of clinical finding and other relevant test such as ovarian ultrasonography (In fertility applications); abdominal or testicular ultrasound (intersex or testicular function applications); measurement of sex steroids (estradiol, Progesterone, Testosterone), FSH, Inhibin B (For fertility), and Inhibin A and B (for tumour work up).
2. Conversion of AMH from ng/mL to pmol/L can be performed by using equation  $1 \text{ ng/mL} = 7.14 \text{ pmol/L}$

\*\*\* End Of Report \*\*\*



  
 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)

  
 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST  
 MBBS, MD (PATHOLOGY)

